Regardless, these results suggest that the anti-cancer agent TMZ promotes the expression and activity of MMP9 in vivo, and that prolonged TMZ treatment can cause adverse effects in GBM patients by stimulating metastasis through activation of MMP9. This evidence concerns the gene MMP9 and glioblastoma.